Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Sixmo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Molteni Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
Details:
Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
